Abstract. Inappropriate expression of microRNA (miR) is strongly associated with carcinogenesis. miR-143 was reported to be one of the most prominent miRs implicated in the genesis and progression of human cancer. However, its correlation with cell proliferation and apoptosis in cervical cancer remains to be fully elucidated. In the present study, it was demonstrated that miR-143 is able to suppress the proliferation of cervical cancer HeLa cells and induce cell apoptosis in a time-and dose-dependent manner. The present study also investigated the potential targets of miR-143, extracellular-signal-regulated kinase 5 (ERK5) and its downstream substrate oncoprotein c-Fos, both of which are involved in cell proliferation and apoptosis. Upon increasing the miR-143 level, the ERK5 and c-Fos protein expression was significantly decreased without the effect of ERK5 transcription. Therefore, miR-143 is able to suppress cell proliferation and induce apoptosis in HeLa cells, potentially through negative regulation of ERK5 at its post-transcriptional stage.
Introduction
MicroRNAs (miRs) are a group of endogenous RNAs (containing ~23 nucleotides) that have significant gene expression regulatory roles by pairing to the mRNAs of protein-coding genes to direct their post-transcriptional repression (1) . Approximately 50% of miR genes are located in cancer-associated genomic regions or in fragile sites, and a number of them have been demonstrated to exhibit tumor suppressor activity, while others have been reported to act as oncogenes in various tissues and environments (2) . Rescued expression of downregulated or functionally-deficient miRs and/or inhibition of overexpressed miRs may contribute to rebalancing the expression of large gene clusters implicated in cell differentiation, apoptosis, metabolism, immunity, oncogenesis and cancer (3) .
Previously, it has been demonstrated that the miR clusters miR-143 and miR-145 at the chromosome 5q32 region are downregulated in various human tumors and are able to suppress tumor growth in cancer of the urogenital (4, 5) , digestive (6) and respiratory systems (3), as well as in osteosarcoma (7), breast cancer (8) and leukemia (9) . Furthermore, numerous types of human cancer cell exhibit a markedly reduced expression of miR-143 and miR-145 compared to normal tissues (10) . Accumulating evidence indicates that miR-143 may act as an anti-oncomir in a number of types of cancer (11) .
Cervical cancer exhibits an aberrant cellular miR expression pattern (12) . miR-143 expression has been reported to be downregulated in human cervical cancer tissues (13) . Furthermore, previous studies have revealed that miR-143 is downregulated in HPV-induced pre-neoplastic lesions, which suggests that miR-143 may have a significant role in the early stages of cervical cancer development (13, 14) . However, the mechanism of miR-143 in apoptosis and cell cycle progression during cervical cancer and the mechanisms underlying these processes remain to be elucidated. miRs are able to regulate multiple target genes simultaneously (15) . miR-143 has been demonstrated to target Kirsten rat sarcoma viral oncogene homolog (KRAS) (16) , matrix metalloproteinase-13 (7), epithelial-mesenchymal transition (17) , cyclooxygenase-2 (6) and cluster of differentiation 44v3 (3), and is able to suppress cell growth and metastasis in vitro and in vivo in several types of tumor (13) . Among the target genes regulated by miR-143, in silico screening of gene targets for miR-143 was performed using TargetScan (www.targetscan.org). Extracellular-signal-regulated kinase 5 (ERK5), which is an upstream gene of mitogen-activated protein kinase (MAPK), has been reported to be a potential target of miR-143 and to be closely associated with tumorigenesis (18) . There is clinical evidence that an increase in ERK5 signaling may be associated with cancer progression.
For example, miR-143 targeting by ERK5 was demonstrated in prostate cancer (19) , bladder cancer (10), gut tumors (20) , colon carcinoma (21) and DLD-1 cells (22) . This may be due to the fact that ERK5 is able to phosphorylate c-Fos, which is a highly inducible and unstable transcription factor, and has a variety of functions in cell proliferation, differentiation and transformation regulation (23) . The activity and stability of c-Fos is affected by several kinases, including ERK1/2, ribosomal s6 kinase, c-Mos, ERK5 and p38, via phosphorylation (23) . Therefore, this suggests that targeted therapies against ERK5 may have a more widespread clinical application in numerous types of cancer.
In the present study, the effect of miR-143 overexpression was evaluated in HeLa cervical cancer cells. miR-143 expression in the transfectants was assessed by northern blotting. The results indicated that miR-143 overexpression reduced HeLa cell viability in a dose-and time-dependent manner compared to control cells, via cell counting and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The present study also identified that the mechanism of miR-143 inhibition of migration and invasion of HeLa cells may be via targeting ERK5 and its downstream oncoprotein c-Fos.
Materials and methods
Cell culture, cell viability and morphological study. Human cervical cancer HeLa cells (obtained from the cell bank of the Institutes for Biological Sciences, Shanghai, China) were cultured in RPMI-1640 (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% (v/v) heat-inactivated fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (Sigma-Aldrich; EMD Millipore, Billerica, MA, USA), under an atmosphere of 95% air and 5% CO 2 at 37˚C. Cell viability was determined by cell counting and MTT assays. Briefly, the medium in each well was replaced with 250 µl of fresh medium containing 0.5 mg/ml MTT (Sigma-Aldrich; EMD Millipore) and incubated for 4 h at 37˚C. Following removal of the medium and MTT, the remaining crystals were dissolved in 150 µl dimethyl sulfoxide (Sigma-Aldrich; EMD Millipore) and the plate was agitated for 5 min in the dark. The absorbance at 490 nm was measured using an ELx800 enzyme immunoassay analyzer (BioTek Instruments, Inc. Winooski, VT, USA). In a cell counting assay, 50 µl of cells was added to 450 µl trypan blue (1:10 dilution) and the calls were counted using a hemocytometer. The results are presented as the mean ± standard error of quadruplicates of a representative experiment.
Transient transfection. A total of 20 or 40 nM of precursor-miR-143 (Pre-miR-143; 5'-UGA GAU GAA GCA CUG UAG CUC-3') or random sequence negative control (5'-UUC UCC GAA CGU GUC ACG UTT-3') (Ambion; Thermo Fisher Scientific, Inc.) were transfected into 5x10 5 HeLa cells using Lipofectamine ® 2000 transfection reagent (Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. A second cell transfection was performed at 48 h after the first transection using the same transfection method for cell viability analyzed by cell counting. To confirm the efficiency of transfection, northern blotting was performed following transient transfection.
Northern blotting. Total RNA for reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis was extracted using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.) as described previously (24) and separated on a 10% polyacrylamide TBE-urea mini-gel (Invitrogen; Thermo Fisher Scientific. Inc.) for miR analysis, followed by electroblotting onto a Hybond N nylon filter (GE Healthcare Life Sciences, Chalfont, UK). The membrane was hybridized with an end-labeled oligonucleotide probe (Promega Corporation, Madison, WI, USA) for miR-143 (5'-TGA GCT ACA GTG CTT CAT CTC A-3') for 2 h at 42˚C and washed 3 times with Hank's balanced salt solution buffer. The hybridization was performed in Rapid-Hyb buffer (GE Healthcare Life Sciences). The blot was probed for U6 as a control for equal loading (25, 26) . Data were analyzed using a Storm 860 PhosphorImager (GE Healthcare Life Sciences). Densitometric analysis was performed by Healthcare ImageQuant TL 7.0 Image Analysis Software (GE Healthcare Life Sciences), as described previously (24).
Target genes. The gene targets for miR-143 were predicted using TargetScan (www.targetscan.org) and the potential target of interest, ERK5, was screened as previously described (19) .
RT-qPCR.
A total of 100 ng RNA was extracted with the miRNeasy kit (Qiagen GmbH, Hilden, Germany) and was further subjected to RT using a reverse transcription kit (New England BioLabs, Inc., Ipswich, MA, USA) according to the manufacturer's protocol. qPCR was performed using a SYBR Green Real-Time PCR Master Mix (Bio-Rad Laboratories, Inc., Hercules, CA, USA) on an iCycler (Bio-Rad Laboratories, Inc.). The PCR reaction consisted of 40 cycles (94˚C for 45 sec, 55˚C for 30 sec and 72˚C for 30 sec) following an initial denaturation step (95˚C for 20 sec). The sequences of the primers used in the present study were as follows: ERK5 forward, 5'-CCT TCG ATG TGA CCT TTG AC-3' and reverse, 5'-TGA CAC CAT TGA TCT GAC CC-3'; β-actin forward, 5'-ATC GTG CGT GAC ATT AAG GAG AAG -3' and reverse, 5'-AGG AAG GAA GGC TGG AAG AGT G-3'. Expression of ERK5 relative to β-actin was determined using the 2 -ΔΔCq method (27) .
Flow cytometric analysis of cell cycle and apoptosis. Cells were harvested by trypsinization, centrifuged at 400 x g for 5 min at 4˚C, suspended in 0.1 ml of phosphate-buffered saline (PBS) and subsequently fixed by addition of 1.0 ml 70% cold ethanol. Following pelleting and removal of ethanol, RNA was extracted using 1 unit of RNase A (Sigma-Aldrich; EMD Millipore). The cells were stained with 50 µg/ml propidium iodide (PI; Sigma-Aldrich; EMD Millipore) for 30 min at room temperature. The DNA content was subsequently analyzed using cytofluorometry and cell cycle analysis was performed using FACScan software (BD Biosciences, Franklin Lakes, NJ, USA), as described previously (19) . To analyze apoptosis, cells were washed in PBS and centrifuged at 400 x g for 5 min at 4˚C. Cells were resuspended in binding buffer (Biolegend, Inc., San Diego, CA, USA), and 5 µl of fluorochrome-conjugated Annexin V-fluorescein isothiocyanate (FITC; Roche Diagnostics, Meylan, France) and 10µl PI solution were added and incubated with the cells for 10 min at 4˚C. The percentage of Annexin V-FITC-positive cells was immediately analyzed using a flow cytometer and the data were analyzed using the Modfit LT software for Windows version 3.2 (Verity Software House, Inc., Topsham, ME, USA).
Western blotting. The cells were homogenized in chilled lysis buffer comprising 10 mM Tris-HCl (pH 7.4), 1% NP-40, 0.1% deoxycholic acid, 0.1% sodium dodecyl sulfate (SDS), 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid and 1% protease inhibitor cocktail (Sigma-Aldrich; EMD Millipore) for 30 min on ice. Following centrifugation at 16,000 x g for 20 min at 4˚C, the supernatants were collected as protein samples. Protein concentrations were assessed with a DC protein assay kit (Bio-Rad Laboratories, Inc.). A total of 10 µg of protein lysate was used for western blotting and separated by 10% SDS-PAGE, followed by electroblotting onto a polyvinylidene difluoride membrane (DuPont, Boston, MA, USA). Following blockage of non-specific binding sites using Tris-Buffered Saline and Tween 20 (TBST) containing 5% non-fat milk for 1 h, the membrane was incubated with rabbit anti-human ERK5 monoclonal antibody (1:1,000 dilution; clone, D3I5V; catalog no. 12950; Cell Signaling Technology, Inc., Danvers, MA, USA) or mouse anti-human c-Fos monoclonal antibody (1:1,000 dilution; clone, 6-2H-2F; catalog no. sc-447; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) overnight at 4˚C. The membranes were washed three times with TBST and incubated further with horseradish peroxidase-conjugated sheep anti-mouse immunoglobulin (Ig) G, horeradish peroxidase (HRP)-linked whole antibody (catalog no. NA931) or enhanced chemiluminescence donkey anti-rabbit IgG, HRP-linked whole antibody (catalog no. NA934V) (GE Healthcare Life Sciences) for 1 h at room temperature. The immunoblots were visualized using an enhanced chemiluminescence detection kit (New England BioLabs, Inc.) following washing three times with TBST. Quantification was performed using Imaging J version 1.45 (National Institutes of Health, Bethesda, MD, USA).
Statistical analysis.
Each experiment was performed in triplicate, with the exception of the MTT assay, which was performed in quadruplicate. All statistical analyses were performed using SPSS version 13.0 (SPSS, Inc., Chicago, IL, USA). Data are presented as the mean ± standard error, and differences between groups were calculated by analysis of variance or χ 2 . P<0.05 was considered to indicate a statistically significant difference. (Fig. 1A) , as compared to negative control transfected cells and blank buffer following normalization to U6 expression (P<0.05).
To evaluate the impact of miR-143 overexpression on the growth of HeLa cells, cell counting and MTT assays were performed on HeLa cells following transient transfection with Pre-miR-143 at 20, 40 and 80 nM respectively. The increased level of Pre-miR-143 (40 and 80 nM) significantly inhibited HeLa cell growth, compared to negative control transfected HeLa cell and blank buffer groups (P=0.091, 0.008 and 0.002, for 20, 40 and 80 nM, respectively) as evaluated by cell counting (Fig. 1B) . This inhibitory effect on cell growth was not an immediate cell response; rather two consecutive cell transfections at an interval of 48 h were required. Furthermore, the cell viability was detected at 0, 1, 2, 3 and 4 days using MTT assays. Notably, the results of the present study have shown that 40 and 80 nM Pre-miR-143 transfection significantly suppresses HeLa cell growth in a dose-and time-dependent manner as compared to the negative control transfected HeLa cells ( Fig. 2; P<0 .001).
miR-143 overexpression induces HeLa cell apoptosis.
Having validated the impact of miR-143 on the growth rate of transfected HeLa cells, the present study additionally characterized the effect of miR-143 overexpression on biological responses, including the cell cycle and apoptosis, using flow cytometry. The representative cell cycle distribution of (Fig. 3A) . Notably, significant dose-dependent increases in the apoptotic fraction and corresponding decreases in the G0/G1 phase of the cell cycle were observed in the Pre-miR-143 transfected cells. By contrast, cells in G2/M phase of the cell cycle were increased from 1.78 to 11.65% (P<0.05) following 20 nM Pre-miR-143 transfection 
miR-143 downregulates the expression of ERK5 and c-Fos.
In silico prediction of gene targets for miR-143 was performed using TargetScan (www.targetscan.org) and ERK5 was screened as a potential target. ERK5, also known as big MAPK, is activated by oxidative stress, hyperosmolarity and certain growth factors (29) . Unlike other MAPK members, ERK5 has a unique large C-terminal region, whose function has not been fully elucidated (30) . It has been shown that ERK5 directly interacts with, phosphorylates and activates a number of transcription factors, including c-Myc, Sap1a, c-Fos, Fos-related antigen 1 and myocyte enhancer factor-2 family members (29) . ERK5 is important for promoting cell proliferation, differentiation and neuronal survival (30) . Its activity has been previously considered to be dependent on its phosphorylation by MEK5; however, post-transcriptional regulation in this process is also considered to play a role, as has been previously reported (19 Fig.5C ). Furthermore, activated ERK5 modulates cell differentiation and proliferation via c-Fos, c-Myc, cyclin D1 and nuclear factor-кB activation. Additionally, c-Fos has been demonstrated to have a regulatory effect via a signaling pathway involving ERK5 (23, 26 ). Therefore, the transcription level and the expression level of c-Fos were also evaluated. Notably, the c-Fox protein expression was reduced concurrently with the downregulation of ERK5 (P<0.05; Fig. 5C ). This indicates that ERK5 may be negatively regulated by miR-143 at the post-transcriptional level, which additionally decreases downstream c-Fos oncoprotein expression.
Discussion miR-143 is one of the most prominent miRs implicated in the genesis and progression of human cancer. It has been implicated in the promotion of tumor growth, proliferation, apoptosis resistance and resistance to gemcitabine-based chemotherapy (31) . Furthermore, a number of studies have identified that miR-143 was downregulated in various tumor types (32) (33) (34) (35) . The expression levels of miR-143 and -145 were observed to be decreased in the majority of human gastric cancer cases, and growth inhibition and increased sensitivity to 5-fluorouracil was reported following transfection with miR-143 (36) . It has also been reported that miR-143 expression is significantly downregulated in bladder tumor tissues compared with normal adjacent tissues, and miR-143 transfection into EJ and T24 cells significantly inhibited cell proliferation (37) . Taken together, the results of a number of studies, including the present, support the hypothesis that miR-143 may be one of the most relevant tumor suppressors among the class of miRs. However, limited efforts have been made to elucidate the role of miR-143 in cervical cancer. The molecular mechanism modulated by miR-143, leading to cell growth inhibition and death remains to be fully elucidated and the role of miR-143 in regulation of the cell cycle and apoptosis is unclear. Lin et al (38) used a direct sequencing method to characterize the profiles of miRs and other small RNA segments for six human cervical carcinoma cell lines and five normal cervical samples, confirmed with a panel of 29 matched pairs of human cervical cancer and normal cervical samples. Reduced expression of miR-143 and increased expression of miR-21 were observed in cervical cancer samples, suggesting the potential value of these miRs as tumor markers (24, 38) .
The present study demonstrates that miR-143 is a negative regulator of HeLa cell growth. It may additionally be speculated that miR-143 can induce apoptosis, at least in part, via negatively regulating ERK5. As in the present transfection experiments ERK5 mRNA level was unaltered, contrasting to the significant change in ERK5 protein levels, it may be proposed that the main mechanism of miR-143-induced ERK5 suppression occurs at a post-transcriptional level.
To the best of our knowledge, the results of the present study comprise the first report of a causal association between miR-143 and G2-M progression. Zen et al (39) reported that downregulation of MAPK7 by small interfering RNA suppressed the growth of SNU449 cells, which comprise the HCC cell line with the greatest amplification and overexpression of MAPK7. ERK5, which is phosphorylated during the G2/M phases of the cell cycle, may regulate entry into mitosis in SNU449 cells (40) . As a significant step in determining its role in cervical tumorigenesis, the present study identifies a novel function for miR-143/ERK5 in the regulation of G2-M transition.
ERK5 has been demonstrated to inhibit cancer cell viability, achieved in part by inhibiting the nuclear export of c-Fos and disrupting the interaction of c-Fos with ubiquitin protein ligase E3 component N-recognin 1 by phosphorylating Ser32 (23) . Additional mechanisms and targets of miR-143 besides ERK5 are likely to contribute to miR-143-induced tumor cell growth inhibition. It has been reported that miR-143 is significant in suppressing colorectal cancer cell growth via inhibition of KRAS translation (41) . Additionally, restoration of miR-143 expression in colon cell lines decreased tumor cell growth and soft-agar colony formation, and downregulated DNA (cytosine-5)-methyltransferase 3A (DNMT3A) expression in terms of mRNA and protein levels. DNMT3A has been demonstrated to be a direct target of miR-143 by luciferase reporter assay (42) .
An improved understanding of the signaling pathway investigated in the present study will bring us closer to understanding the molecular mechanisms underlying cervical cancer and may lead to the development of novel approaches for detection and therapy. Taken together with the results of previous correlational studies on miR-143 and ERK5, the results of the present study indicate that strategies rescuing miR-143 expression, enhancing the miR-143/ERK5 interaction, or inhibiting ERK5 expression may have a strong rationale for therapeutic applications in the treatment of cancer.
